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Abstract The novel oral anticoagulants or direct oral antico-
agulants (DOAC) are becoming more common in clinical
practice for the prevention of stroke in non-valvular atrial
fibrillation (NVAF). The availability of several agents with
similar efficacy and safety for stroke prevention in NVAF
patients offers more selection, but at the same time requires
certain knowledge to make a good choice. This comparative
analysis provides an appraisal of the respective clinical trials
and highlights much of what remains unknown about four
FDA-approved agents: dabigatran, apixaban, rivaroxaban,
and edoxaban. It details how the DOACs compare to warfarin
and to one another summarizes pharmacologic and pharma-
codynamic properties, and drug interactions from the stand
point of practical consequences of these findings. Common
misconceptions and reservations are addressed. The practical
application of this data is intended to help choosing the most
appropriate agent for individual NVAF patient.
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Introduction
In 2010, the FDA approved dabigatran for stroke prevention
in patients with non-valvular atrial fibrillation (NVAF) and
ended a long era of vitamin K antagonists (VKA) as the main-
stay of oral anticoagulation for this indication [1]. Within the
last 5 years, four direct oral anticoagulants (DOACs):
dabigatran, rivaroxaban, apixaban, and edoxaban, were
assessed in large phase III clinical trials, compared to either
warfarin [2–5] or aspirin [6], for stroke prevention in patients
with NVAF. Results of these trials have led to FDA approval
of these agents, along with endorsement by a growing number
of guidelines and regulatory bodies worldwide [7–20]. Al-
though there are abundant data on DOAC efficacy and safety
compared to warfarin, and a growing experience on their in-
teraction with other medications, there is a general lack of
knowledge of the application of these findings into clinical
practice. In the end, choosing the most appropriate DOAC
for an individual NVAF patient remains complicated. This
review is intended to concentrate on useful practical implica-
tions of our knowledge about DOACs (formerly known as
novel anticoagulants NOACs), and to resolve some miscon-
ceptions, and reservations regarding this group of anticoagu-
lants to help in every day application of these agents.
Background
VKAs inhibit the carboxylation of all vitamin K-dependent
procoagulant factors II, VII, IX, X, but also have the Boff
target^ effect of inhibiting the natural anticoagulants, protein
C, and protein S. In contrast, DOACs target specific proteins
in the coagulation cascade. These targeted factors were well
chosen given their central participation in the coagulation cas-
cade. Factor Xa serves as the convergent enzyme where the
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intrinsic and extrinsic pathways meet to form the final com-
mon pathway of prothrombin activation. It is estimated that
one molecule of factor Xa is responsible for generating more
than 1000 thrombin molecules [21]. Direct factor Xa inhibi-
tion (rivaroxaban, apixaban, edoxaban) turns off prothrombin
activation upstream, thus limiting available thrombin. More-
over, unlike low molecular weight heparin or pentasaccharide
therapy, direct factor Xa inhibitors have access to factor Xa
sequestered within the prothrombinase complex. Targeting
thrombin by dabigatran is also quite logical, as thrombin
cleaves fibrinogen to fibrin as the final step of clot formation.
Thrombin activates factor XIII, which stabilizes the develop-
ing clot. Moreover, thrombin self-amplifies its own generation
by activating factors Vand VIII, and is the most potent platelet
activator.
General characteristics
There are several characteristics which distinguish DOACs, as
a group, fromVKAs. First, they have rapid onset of action (1–
3 h) and, consequently, do not require Bbridging^ with paren-
teral anticoagulants. Second, there is no need for routine mon-
itoring of anticoagulation. Third, they have similar (7–15 h)
half-lives. Fourth, they are all, to some extent, partially elim-
inated by the kidney: 80 % of dabigatran, 50 % of edoxaban,
35 % of rivaroxaban, and 25 % of apixaban [5, 17]. Patients
with impaired kidney function should therefore use these
medications with caution. Despite similar elimination kinetics,
the dosing frequency differs between the agents; dabigatran
and apixaban are dosed twice daily while rivaroxaban and
edoxaban are given once a day. Patients with busy schedule
or compliance concerns might do better with agents dosed
once a day. A summary of characteristics with meaningful,
practical implications are provided (Table 1).
Providers should be aware of the characteristics that distin-
guish DOACs from one another. For example, only 6–7 %
gastrointestinal absorption of dabigatran implies that slight
fluctuations in absorption or elimination may have a profound
impact on plasma levels. To reduce the impact of varying
gastrointestinal acidity on pro-drug absorption, dabigatran is
formulated with tartaric acid [22]. Therefore, breaking,
chewing, or emptying the contents of the capsule is prohibited
and the patients are instructed to swallow the capsule whole.
Moreover, dabigatran capsules are susceptible to ambient
moisture. Consequently, medication storage must be in the
original bottle or blister package until use. The tartaric acid
spherules may be responsible for a 5–10 % incidence of dys-
pepsia [2]. Patients with peptic ulcer disease, subtotal or total
gastrectomy, or gastric bypass surgery should rather avoid
dabigatran or use it with caution. It is also noteworthy that
rivaroxaban at 15 and 20 mg doses must be taken with food
because of higher bioavailability (from 66 to more than 80 %)
[23]. The other DOACs do not have this requirement even
though edoxaban has 6–22 % better [24] absorption when
taken with food. Apixaban and rivaroxaban have similar bio-
availability when administered in crushed form and therefore
can be administered via a nasogastric tube [25]; no data are
available yet on bioavailability of crushed tablets of edoxaban.
Although less frequent than warfarin, there are important
drug interactions to consider. There are two main mechanisms
by which drug interactions occur with DOACs which are clin-
ically relevant (Table 1). The P-glycoprotein (P-gp) transport-
er system serves to secrete medication back into the intestinal
lumen, bile, and urine, thus reducing drug exposure [26].
Medications which induce this system will, thereby, reduce
drug exposure. Conversely, competitive inhibition will in-
crease drug exposure. The hepatic cytochrome p450 CYP3A4
is the other important pathway in the metabolism of all
DOACs, with the exception of dabigatran [20, 23, 24]. Med-
ications that impact both P-gp and CYP3A4 pathways may
influence the effect of DOACs [17–24]. Strong inducers to
remember include carbamazepine, phenytoin, rifampin, St
John’s wort, and tipranavir/ritonavir which decrease circulat-
ing DOAC levels. Strong inhibitors include itraconazole, ke-
toconazole, lopinavir/ritonavir, indinavir, and voriconazole
which increase DOAC levels. Such drugs should generally
not be co-administered with DOACs [20, 26]. For apixaban,
Table 1 General characteristic of direct oral anticoagulants.
Characteristics Dabigatran Rivaroxaban Apixaban Edoxaban
Renal clearance (%) 80 35 25 50
Bioavailability (%) pH dependenta 6–7 Food dependentb 66–≥80 Food independent 50 Food independent 62
Medication storage In original bottle or
blister package
Room temperature Room temperature Room temperature
Liver metabolism: CYP3A4 metabolism No Yes Minor Minor
Impacted by P-glycoprotein transporter system Yes Yes Yes Yes
a Ten milligram dose has oral bioavailability independent of food but 15 and 20 mg doses of rivaroxaban have achieved high bioavailability (≥80 %)
when taken with food
b Tartaric acid added into the dabigatran capsule to ensure optimal and gastrointestinal pH independent absorption is responsible for 5–10% incidence of
dyspepsia
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Table 2 Interaction of direct oral
anticoagulants with commonly
used cardiovascular medications
Medications Dabigatran Rivaroxaban Apixaban Edoxaban
Quinidine Use with cautiona Use with cautiona No data Use with cautiona
Verapamil Use with cautiona, b Minor effect No data Use with cautiona
Amiodarone Use with cautiona Use with cautiona No data Use with cautiona
Dronedarone Avoid Use with cautiona No data 50 % dose reductionc
Ranolazine No effect Use with cautiona No data No data
Digoxin No effect Minimal effect No effect Minimal effect
Atorvastatin Minimal effect No effect No data No effect
Diltiazem No effect Use with cautiona Use with cautiona No data
Carvedilol No effect Minimal effect No data No data
Felodipine Minimal effect Use with cautiona No data No data
Prazosind Avoid Avoid Avoid Avoid
a “Use with caution” indicates that the effect on DOAC exists but does not require dose adjustment unless another
interaction is present (concomitant use of other medication with additive interaction or CrCl 30–50 mL/min)
b European package insert and European Rhythm Association Practical Guide recommend using 110 mg dose of
dabigatran
c American package insert does not require dose reduction
dAlthough the prescribing informations recommend that DOACs not to be administered in conjunction with the
P-gp inducer like rifampin, studies have not been conducted with other P-gp-inducing medications like prazosin
and, therefore, should be avoided, pending the availability of additional data
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most of the hepatic clearance occurs without metabolism [27].
Therefore, the US package insert recommends reducing the
dose of apixaban from 5 to 2.5 mg twice daily when
co-administered with a strong CYP3A4 and P-gp inhibitors
and to avoid apixaban use if the patient already requires a dose
reduction due to other clinical cofounders (age >80, weight
<60 kg, creatinine >1.5). The European package insert recom-
mends avoiding apixaban use with a strong CYP3A4 and
P-gp inhibitors. While changes in CYP3A4 do not appear to
greatly impact edoxaban metabolism, caution is warranted
until more definitive interaction data are available [28].
Information on dose adjustment and interaction of DOACs
with commonly used cardiovascular medications in patients
with NVAF are important to review (Table 2). Therapy should
be tailored for each patient, not only taking into account
coexisting medications but also comorbidities, including renal
and liver function, general bleeding risk, and propensity for
thrombosis.
Comparative efficacy and safety
In general, the clinical efficacy of DOACs in the four large
clinical trials, enrolling over 70 thousand patients, was similar
to warfarin [2–7, 29–34]. The Bstatistical evidence of
superiority^ of dabigatran over warfarin to prevent ischemic
stroke relied on a very tight margin of 0.98 for 95 % confi-
dence interval [0.76 (0.60–0.98), p = 0.03]. If one realizes that
over 18 thousand patients were necessary to achieve this dif-
ference, the practical meaning of this superiority seems to be
rather elusive. The real advantage of these new agents is the
improved safety margin, particularly evident for apixaban and
edoxaban.
General trial characteristics
To comprehend the combined results of these randomized
trials, it is important to review the differences between studies
(Table 3). The RE-LY study [2] was an open, blinded endpoint
study that compared blinded doses of dabigatran 110 or
150 mg twice daily to open-label dose-adjusted warfarin. Lo-
cal investigators were not blinded as to which drug was ad-
ministered. The other three trials were double blinded,
double-dummy trials comparing a once daily 20 mg dose of
rivaroxaban (ROCKET AF) [3], twice daily, 5 mg dose of
apixaban (ARISTOTLE) [4], and two doses (30 and 60 mg)
of edoxaban, once daily (ENGAGEAF-TIMI) [5], respective-
ly, to warfarin.
While doses of dabigatran were fixed, Xa inhibitor trials
incorporated pre-defined criteria for dose reduction at ran-
domization (Table 3). The ENGAGE-AF investigators also
employed criteria for post-randomization edoxaban dose
modifications. Edoxaban dosing, depending on the treatment
arm and clinical characteristics, ranged from 60 to 15mg daily
[2–5].
Patients with severe renal failure were excluded from all of
these trials. Each trial had pre-specified CHADS2 scores for
inclusion. The ROCKETAF and ENGAGE AF trials recruit-
ed patients with CHADS2 score ≥2. Inclusion criteria for
RE-LY and ARISTOTLE included scores ≥1 [2–5].
The primary efficacy endpoint (stroke/TIA and systemic
embolism) was identical for all four trials. The principal safety
endpoint was major bleeding defined by the International So-
ciety for Thrombosis and Haemostasis (ISTH) criteria for all
trials. The ROCKET AF trial included a combination of ma-
jor, plus clinically relevant non-major bleeding [2–5].
Patients were followed for nearly 3 years in the ENGAGE
AF trial and for about 2 years in the other three trials.
The median time spent within the therapeutic range for the
warfarin arm was the highest in ENGAGE AF and the lowest
in the ROCKETAF trial. The impact of warfarin management
on the comparative analysis of DOACs efficacy and safety is
discussed separately below.
Trial population characteristics
Differences in NVAF patient inclusion criteria, mainly
CHADS2 score, resulted in significant differences in clinical
characteristics of the recruited populations (Table 3). These
differences should be kept in mind when comparing
thromboembolic and bleeding rates between studies. The
mean CHADS2 score was higher in ROCKET AF compared
to RE-LY and ARISTOTLE trials. The mean CHADS2 score
was intermediate in the ENGAGE AF population. Nearly
90 % of participants in the ROCKET AF trial and 53 % of
ENGAGE AF participants had a CHADS2 score ≥3. In con-
trast, slightly less than one third of RE-LY and ARISTOTLE
trial participants had CHADS2 scores of similar severity.
ROCKETAF and ENGAGE trials had the highest proportion
of patients with CHF (about 60 %) compared to about one
third in the other two trials. More than half of ROCKET AF
patients had a history of prior stroke. By comparison, prior
stroke was present in only 20–30 % of patients in the other
three trials [2–5].
There are several practical implications of these differences
worth considering. First, these study population differences
limit inter-trial outcome comparisons. Neither efficacy nor
safety of one agent can be indirectly compared to another. This
is particularly true for rivaroxaban and the high CHADS2
scores of ROCKET-AF. Second, meta-analyses must take into
Table 3 Characteristics of phase III clinical trials of direct oral anticoagulants
Characteristics RE-LY (dabigatran) ROCKETAF (rivaroxaban) ARISTOTLE (apixaban) ENGAGE AF (edoxaban)
Design Randomized, open
labela
Randomized, DB/DD Randomized, DB/DD Randomized, DB/DD
Dosing 150 mg, 110 mg
twice daily
20 mg daily 5 mg twice daily 60 mg, 30 mg daily
Dose adjustment/criteria No If CrCl 30–49 mL/min
then 15 mg
If ≥2 factors: age ≥80 years,
body weight <60 kg,
creat ≥1.5 mg/dL then 2.5 mg
If CrCl 30–50 mL/min or
weight ≤60 kg or potent
P-gp inhibitorb then
50 % dose
CrCl exclusion 30 mL/min 30 mL/min 25 mL/min 30 mL/min
CHADS2 score inclusion
criteria
≥1 ≥2 ≥1 ≥2
Primary efficacy endpoint Stroke/TIA and SE Stroke/TIA and SE Stroke/TIA and SE Stroke/TIA and SE
Primary safety endpoint Major bleeding Major plus CRNM bleeding Major bleeding Major bleeding
Trial size 18,113 14,264 18,201 21,105
Age (years), median (IQR) 72±9c 73 (65–78) 70 (63–76) 72 (64–78)
CHADS2 (mean) 2.1 3.5 2.1 2.8
CHADS2 ≥3 (%) 32 87 30 53
Heart failure 32 62 35 57
Stroke/TIA or SE 20d 55 19 28
Median follow-up (years) 2.0 1.9 1.8 2.8
Early discontinuation
DOAC (%) 20.7/21.2 35.4 25.3 33.0/34.3
VKA (%) 16.6 34.6 27.5 34.4
CRNM clinically relevant non-major bleeding, DB/DD double blind, double dummy, IQR interquartile range, DOAC direct oral anticoagulant, SE
systemic embolism, TIA transient ischemic attack, VKA vitamin K antagonist, CrCl creatinine clearance
a Patients were unblended with respect to dabigatran or warfarin assignment; however, all investigators, coordinating center members, the steering
committee, the event adjudication committee, and the sponsor were blinded during event ascertainment and analyses
b Strong P-gp inhibitors such as dronedarone, quinidine, or verapamil
cMean±SD
dNo data on SE
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account differences in patient risk characteristics to be useful
for clinical application. Third, in low risk patients (CHADS2
≤2), clinicians can apply the results directly from RE-LY and
ARISTOTLE.
Although dose adjustment was allowed at randomiza-
tion in all three Xa inhibitor trials, practical application of
these rules was quite different; only 5 % of ARISTOTLE
trial participants had their dose reduced, compared to
21 % of patients in ROCKET AF, and 25 % of patients
in the ENGAGE AF study. This indicates that dose ad-
justment of rivaroxaban and edoxaban was much better
explored than apixaban, and this information should be
discussed with the patient while deliberating on the choice
of a DOAC for someone who would require dose modi-
fication. A post hoc analysis of RE-LY data showed that
using 110 mg dose of dabigatran for NVAF patients
≥80 years of age or treated with verapamil (dose adjust-
ment consistent with European label) further improved its
overall net clinical benefit [35]. While this concept of
Btailored dosing^ for individual patients is attractive, the
lack of direct trial data for dabigatran dose adjustments
decreases the validity of this approach. Moreover, avail-
able formulations of dabigatran limit the applicability of
this concept in the USA.
Co-administration of aspirin was allowed in all four
clinical trials. The highest proportion of study participants
taking aspirin was in ROCKET AF trial (35 %), followed
by ENGAGE AF (29 %), ARISTOTLE (24 %), and
RE-LY (21 %) trials. But the latter was the only study
that allowed recruitment of patients on clopidogrel (5 %
of participants) [2–6, 33]. The proportion of patients
taking antiplatelet agents impacts the bleeding rate and
needs to be included into any comparative analysis of
safety outcomes. Furthermore, this may impact the deci-
sion of which anticoagulant to use for patients who re-
quire concurrent antiplatelet therapy.
Individual effectiveness and safety in relation to warfarin
The results of the DOAC trials are generally reported
from an intention to treat perspective. From a trialists
viewpoint, analyzing and reporting the results from an
Bintension to treat^ perspective is statistically correct, eth-
ically fair, and methodologically pure. Yet, in the end, the
on-treatment event rates are what really matters, both to
patients and practitioners alike, because it informs what
happens when the medication is actually taken. From a
patient perspective, an intention to treat analysis reflects
information on what would happen if a patient is pre-
scribed a DOAC, regardless of compliance.
The higher treatment discontinuation rates in the ROCKET
AF and ENGAGE AF trials (over 30 %), compared to RE-LY
and ARISTOTLE trials (over 20 %), analyzed with an
intention to treat approach, would negatively impact thrombo-
embolic rates for the former trials. This effect is compounded
by the higher stroke risk population in ROCKET AF and
ENGAGE AF, as well as the longer follow-up period in EN-
GAGE AF [2–6]. The effect of a higher, premature discontin-
uation rate of rivaroxaban and edoxaban on their relative effi-
cacy can be appreciated by an on-treatment analysis. This
approach shows superiority over warfarin for both
rivaroxaban (HR 0.79, 0.66–0.96; p = 0.02) and edoxaban
60 mg (HR 0.79, 0.63–0.99; p = 0.002) for prevention of
stroke and systemic embolization [7]. By the same reasoning,
however, the higher discontinuation rates would favorably
impact bleeding rates of rivaroxaban and edoxaban.
In the ENGAGE AF-TIMI 48 study, NVAF patients with
creatinine clearance >95 mL/min had an increased rate of
ischemic stroke with edoxaban 60 mg once daily compared
to patients treated with warfarin. Therefore, the FDA restricted
the use of this anticoagulant to those with creatinine clearance
lower than 95 mL/min [13]. This restriction seems to have
rather limited practical consequences as few NVAF patients
have such a high creatinine clearance.
For prevention of systemic embolism only, rivaroxaban
was superior to warfarin (in the Bas treated^ population, see
Table 4) and the other DOACs were non-inferior or have no
available data (dabigatran). Accordingly, for NVAF patient
with the history of systemic embolization, rivaroxaban might
be the preferred agent.
The principal efficacy outcome, used in all four trials, was a
combination of stroke and systemic embolization that includ-
ed the safety element of hemorrhagic stroke. This not only
double counted medication effect and overestimated the net
benefit of the DOACs but also provided misleading informa-
tion. Proponents would argue that patients do not distinguish
stroke types and might tend to lump hemorrhagic and ische-
mic strokes together. However, this endpoint may be decep-
tive when it comes to patient care. For the patient with a very
high risk of thromboembolism and very low risk of bleeding,
the DOAC with the best ischemic rather than global stroke
reduction would be desired. In this case, only dabigatran at the
higher dose of 150 mg twice a day was superior to warfarin to
prevent ischemic stroke (Table 4). The lower dose of
edoxaban, 30 mg, was the only DOAC that was inferior to
warfarin. All other DOACs and other doses were non-inferior
to warfarin [2–6].
The benefit-to-risk ratio of dabigatran 150 mg vs warfarin
was less favorable in NVAF older than 75 years compared to
younger individuals [33, 35, 36]. For this reason, dabigatran
dose of 110 mg would be more appropriate for older patients.
However, this dose of dabigatran is not approved in the USA.
For elderly patients, the net benefit likely favors one of the
factor Xa inhibitors.
Apixaban and both doses of edoxaban were associated
with a significantly lower rate of major bleeding, while
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all the other DOACs were non-inferior to warfarin. All
DOACs, except dabigatran dose of 150 mg, were asso-
ciated with significantly lower rates of fatal bleeding.
Hemorrhagic stroke rate and intracranial bleeding were
significantly lower in all DOACs, at all doses, compared
to warfarin. Only low dose edoxaban demonstrated a
lower rate of gastrointestinal bleeding while dabigatran
dosed at 150 mg, rivaroxaban, and edoxaban at 60 mg
showed a significantly higher rate of gastrointestinal
bleeding compared to the VKA arm; apixaban and
dabigatran at 110 mg showed the same bleeding rate as
warfarin [2–6].
Patients randomization to either apixaban or edoxaban ex-
perienced improved overall survival rates relative to
warfarin-treated patients. A trend toward improved survival
was noted for dabigatran and rivaroxaban. Cardiovascular
death rates were significantly lower for dabigatran and
edoxaban-treated patients [2–6].
Comparison of DOACs amongst themselves
The meta-analyses of DOACs as a whole group showed the
following: better protection from stroke and systemic embo-
lism, better safety from intracerebral hemorrhage, all-cause
mortality, and vascular mortality compared to warfarin. Major
bleeding and gastrointestinal bleeding rates were similar to war-
farin [37, 38]. This global comparison to warfarin provides an
endorsement for DOACs, but has minimal practical usefulness,
as the individual patient will take just one agent of this group.
Several indirect, comparative analyses [31, 39–41]
amongst DOACs were performed to identify agents with su-
perior efficacy or safety from among the group. Such compar-
ison, however, is seriously impacted by the differences in trial
design, patient characteristics, and methods of outcome mea-
surement [7, 42]. To compensate for these differences between
trials, only NVAF patients with CHADS2 ≥3 were evaluated
in one study [30]. This analysis showed that therapy with both
doses of dabigatran, apixaban, and rivaroxaban had similar
efficacy, but apixaban therapy was associated with a lower
rate of major hemorrhage compared to dabigatran 150 mg
and rivaroxaban. Very similar efficacy of dabigatran 150 mg,
apixaban, and rivaroxaban were also reported when only
NVAF patients with prior stroke (secondary prophylaxis) were
analyzed [39].
In summary, indirect comparisons of DOACs, adjusted for
patient characteristics, provide some meaningful additional
information about these agents in the absence of direct com-
parisons, which are unlikely to be forthcoming. The reader
must cautiously interpret these data given the methodological
flaws associated with such comparisons.
Table 4 Clinical outcomes of clinical trials with direct oral anticoagulants (DOACs) in relation to warfarin
DOAC vs VKA








48 (edoxaban) 30 mg
150 mg 60 mg
Ischemic stroke 1.11 (0.89–1.40)a 0.94 (0.75–1.17) 0.92 (0.74–1.13) 1.41 (1.19–1.67) p < 0.001
0.76 (0.60–0.98)a p = 0.03 1.00 (0.83–1.19)
Systemic embolism Not reported 0.23 (0.09–0.61) p = 0.003 0.87 (0.44–1.75) 1.24 (0.72–2.15)
0.65 (0.34–1.24)
Hemorrhagic stroke 0.31 (0.17–0.56) p < .0001 0.59 (0.37–0.93 p = 0.024) 0.51 (0.35–0.75) p < 0.001 0.33 (0.22–0.50) p < 0.001
0.26 (0.14–0.49 p < 0.001 0.54 (0.38–0.77) p < 0.001
Major bleed 0.80 (0.69–0.93) p = 0.003 1.04 (0.90–1.20) 0.69 (0.60–0.80) p < 0.001 0.47 (0.41–0.55) p < 0.001
0.93 (0.81–1.07) p = 0.3 0.80 (0.71–0.91) p < 0.001
Intracranial bleed 0.31 (0.20–0.47) p < 0.001 0.67 (0.47–0.93) p = 0.02 0.42 (0.30–0.58) p < 0.001 0.30 (0.21–0.43) p < 0.001
0.40 (0.27–0.60) p < 0.001 0.47 (0.34–0.63) p < 0.001
Gastrointestinal bleed 1.10 (0.86–1.41) 3.2 vs 2.2b p < 0.001 0.89 (0.70–1.15) 0.67 (0.53–0.83) p < 0.001
1.50 (1.19–1.89) p < 0.001 1.23 (1.02–1.50) p = 0.03
All-cause mortality 0.91 (0.80–1.03) 0.85 (0.70–1.02) 0.89 (0.80–0.98) p = 0.047 0.87 (0.79–0.96) p = 0.006
0.88 (0.77–1.00) p = 0.051 0.92 (0.83–1.01)
Cardiovascular mortality 0.90 (0.77–1.06)a 0.89 (0.73–1.10) 0.89 (0.76–1.04) 0.85 (0.76–0.96) p = 0.008
0.85 (0.72–0.99)a p = 0.04 0.86 (0.77–0.97) p = 0.013
Bold font indicates significantly better result of DOAC in relation to warfarin. Bold and italic font indicates significantly worse result of DOAC
compared to warfarin
a RE-LY reported relative risk instead of hazard ratio (HR); ischemic or uncertain stroke instead ischemic stroke, and vascular mortality instead
cardiovascular mortality
b Incidence/year (%), HR not reported
Limitations of trials
Numerous exclusion criteria used in all four clinical trials of
DOACs left clinicians with a considerable gap of knowledge
about applicability of DOACs in important and commonly
seen medical conditions. Patients with disabling stroke within
the previous 6 months were excluded from dabigatran and
rivaroxaban studies. The trial with apixaban excluded patients
who suffered ischemic stroke within the previous 7 days;
dabigatran and rivaroxaban within the previous 14 days, and
edoxaban within the past 30 days. We have no data for
DOACs used in patients with prior intracranial, intraocular,
spinal, retroperitoneal or traumatic intra-articular bleeding,
and in patients with hemoglobin Hb <10 g/dL or a platelet
count <100,000 because they were excluded from all four
clinical trials [2–5]. Adequate and well-controlled studies of
DOAC use in pregnancy and pediatric populations are not yet
available.
All four clinical trials showed lower risk of hemorrhagic
stroke and intracranial bleed from DOAC therapy compared
to warfarin [2–5, 42]. These results are dependent not only on
DOACs Bperformance^ but also warfarin arm safety data.
Observational Breal life^ studies confirmed this favorable
comparison [43, 44]. However, the Breal life^ risk of cerebral
hemorrhage associated with warfarin [45], documented in a
large Canadian registry, was significantly lower than the rate
observed in the VKA arms of the DOAC clinical trials. These
results, although obtained in a different cohort and clinical
setting, might question the Bundisputable superiority^ of
DOACs over warfarin for the risk of intracranial hemorrhage
implied in the phase III clinical trials.
Dabigatran, used both for patients with NVAF and venous
thromboembolism [46], was associated with increased risk of
myocardial infarction. Additional analysis of the RE-LY study
outcomes ordered by FDA [47] revealed 81 additional events
in the study population including 4 clinically evident and 28
silent myocardial infractions (new Q waves on EKG). This
study confirmed a trend toward an increased incidence of
myocardial infarction in patients receiving dabigatran but the
difference was no longer statistically significant both for 110
and 150 mg doses. Moreover, post-marketing investigations
and clinical registries [43, 44] have not substantiated an in-
creased rate of myocardial infarction in NVAF patients treated
with dabigatran. It also needs to be highlighted that treatment
with dabigatran resulted in significantly lower rates of cardio-
vascular death compared to warfarin [2].
Difficulty achieving therapeutic anticoagulation, dietary
modifications, the necessity of blood collection, visits for
INR assessment, and treatment counselling were among im-
portant factors responsible for suboptimal use of warfarin in
patients with atrial fibrillation. Free of all these inconve-
niences, DOACs give hope for better compliance with oral
chronic anticoagulation in patients with NVAF. However,
the rate of discontinuation in all phase III trials was roughly
the same for warfarin and DOACs. This suggests that adher-
ence to DOACs is disheartening and might not be as good as
expected. However, except for RE-LY, all other studies were
double-dummy, so all patients were equally inconvenienced
by blood testing and counselling. A Breal life^ assessment of
adherence to DOAC therapy is needed to verify this
expectation.
Controversies related to DOACs
DOACs reversal
For patients taking warfarin who are found to have prothrom-
bin time-INR prolongation, reversal can be accomplishedwith
fresh frozen plasma, prothrombin complex concentrate
(PCC), and vitamin K. Although this approach has a long
track record with general endorsement by medical profes-
sionals, there is little data showing clinical outcomes of
Breversed^ to Bnon-reversed^ bleeders. Recently, reported
lack of clinical benefit in warfarin-associated intracranial hem-
orrhage after anticoagulation reversal with PCC calls into
question the clinical significance of this therapy [48]. Also, a
study comparing patients with intracranial bleeding who were
treated with dabigatran, and therefore not Breversed,^ com-
pared to those with warfarin, for whom reversal of anticoagu-
lant therapy was possible, did not show improved clinical
outcomes with reversal [49]. Moreover, clinical outcome data
of bleeding patients on apixaban, and those on warfarin, sug-
gests indirectly that warfarin reversal may not be clinically
beneficial [50].
PCC, highly purified concentrates of clotting factors, have
been touted as potential reversal agents for patients taking oral
direct factor Xa inhibitors. These concentrates are available as
either three-factor or four-factor formulations. The four-factor
formulation contains factors II, VII, IX, and X in addition to
protein C and S. By comparison, the three-factor formulation
does not contain factor VII, protein C, or protein S. In one
study, a four-factor PCC was assessed in 12 healthy individ-
uals given rivaroxaban 20 mg twice daily or dabigatran
150 mg twice daily. In this study, PCC was shown to normal-
ize prolonged prothrombin times in those patients taking
rivaroxaban, but not dabigatran [51]. In another double-blind,
randomized, placebo-controlled, two-way crossover study,
normal volunteers were given edoxaban 60 mg followed by
four-factor PCC (10, 25, or 50 IU/kg) to determine impact on
bleeding duration following skin punch biopsy [52]. In this
study, a dose-dependent reversal of edoxaban’s effects on
bleeding duration, endogenous thrombin potential, and pro-
thrombin time reversal were observed with complete reversal
noted at the highest PCC dose. In a separate healthy volunteer
study, the three-factor PCC was compared to the four-factor
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PCC for reversal of rivaroxaban 20mg twice daily [53]. In this
study, only minimal normalization of the prothrombin time
was achieved with either PCC; however, the three-factor
PCC provided greater changes in thrombin generation. Re-
cently, three-factor PCC was also evaluated for the ability to
reverse the anticoagulation effects of edoxaban [54]. This
study showed that although there was no apparent reversal
of prothrombin time prolongation with three-factor PCC, en-
dogenous thrombin potential was completely reversed. In
summary, both the three-factor and four-factor PCCs likely
work to some degree for reversal of the direct factor Xa inhib-
itors. Neither agent is likely to be effective for reversal of
dabigatran. Based on our experience, we suggest judicious
use of these agents given the propensity for thrombus
induction.
Implementation of an antidote, defined as a substance that
Bneutralizes^ or blocks the anticoagulant agent without chang-
ing any other components of the coagulation system, should
theoretically limit the prothrombotic effect of its use. Several
antidotes for DOACs such as idarucizumab, andexanet alfa,
and aripazine have shown instantaneous or rapid normaliza-
tion of coagulation measures in healthy volunteers and are
currently evaluated in phase III clinical trials [55]. Recently,
the safety of 5 g of intravenous idarucizumab was assessed in
patients suffering a serious bleed or requiring an urgent pro-
cedure. This study showed that normalization of prolonged
clotting tests could be accomplished in 88 to 98 % of the
patients within minutes of administration [56]. Based on these
data, idarucizumab has now been FDA approved for this
indication.
Under circumstances of active bleeding or urgent/emergent
surgery, management of these agents would ideally be guided
by knowledge of circulating drug levels. Circulating drug
levels can be measured directly or indirectly by assessing their
impact on clot-based assays. Direct measurement of circulat-
ing drug levels is currently limited to academic medical cen-
ters. The dilute thrombin time assay supplemented by a spe-
cific, validated calibrator allows an indirect measurement of
dabigatran plasma levels. Available data [57, 58] indicate that
there might be increased bleeding risk if drug concentration at
trough is >200 ng/mL. It was also reported [57] that prolon-
gation of aPTT at trough exceeding two times the upper limit
of normal rangemight be associated with excess bleeding risk.
On the other hand, a normal aPTT in patients treated with
dabigatran was used in a case of an urgent surgery to exclude
any relevant residual anticoagulation effect of this DOAC
[57]. Similarly, direct Xa inhibitors plasma concentration can
also be measure by anti-FXa chromogenic assays using vali-
dated calibrators, but no data on threshold values for bleeding
or thrombosis yet exist to apply this information into decision
making [20]. Wide dissemination of these assays to general
practice settings is therefore of principal importance in the
effort to gain experience and achieve clinical applicability.
Labile INR and the relative effectiveness of DOACs
Relevant quality outcomes for anticoagulated patients include
the frequency of hard events such as major bleeding and
thromboembolism. For warfarin-managed patients, time spent
within the therapeutic range is a well-established surrogate
outcome which directly correlates with the stroke risk. The
correlation with bleeding is variable [59]. The DOAC trials,
like all previous multi-center, multinational trials of
anticoagulation, showed wide variations in INR control be-
tween countries and sites. This has led to questions regarding
the relevance of the overall findings for individual patients, or
countries, with more refined anticoagulation management
systems.
There is an assumption that poor management of warfarin
therapy would favor both the efficacy and safety of DOACs
and, conversely, more time spent within the therapeutic range
would be associated with the loss of benefit of new anticoag-
ulants. The interpretation of the relationships between time in
therapeutic range (TTR) and treatment effect is complex and
requires digestion before drawing firm conclusions. INR con-
trol during warfarin treatment is influenced by multiple
patient-related factors such as age, sex, bodyweight, smoking,
diabetes mellitus, liver failure, congestive heart failure, lung
disease, prior experience with anticoagulation, and concomi-
tant use of other medications, particularly amiodarone or
dronedarone [59]. Other individual-related features, like cul-
tural factors and education, significantly impact
anticoagulation management. Furthermore, differences in so-
cioeconomic status, healthcare systems, and quality of medi-
cal service have profound impact on the efficacy of
anticoagulation management. All these factors have an impact
not only on warfarin management, and therefore TTR, but
also on efficacy and safety of DOACs. Blinded randomization
should account for all of these variables, which are anticipated
to be equally prevalent in both treatment arms. Redistributing
study results based on individual TTR in the warfarin arm
leads to redistribution of younger, better educated patients,
with less comorbidities and greater access to sophisticated
healthcare systems, into the cluster with better TTR values.
Accordingly, the lower risk of stroke and bleeding becomes
associated with better warfarin management. However, this
Bcorrection^ does not happen in the DOAC arm. Thus, using
individual TTR to adjust the effect of treatment violates prin-
ciples of clinical and statistical analysis and annuls the advan-
tages of randomization.
Analyses of the impact of TTR on comparative efficacy
and safety of dabigatran [60], rivaroxaban [61], and apixaban
[62] were performed using center-specific TTR, which better
conserves a fair distribution of factors influencing treatment
performance in both arms of the trial. This approach showed
that the primary endpoints of efficacy and safety, in relation to
warfarin, were consistent across a wide range of center
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specific TTRs for dabigatran, rivaroxaban, and apixaban
[60–62]. Apixaban showed similar efficacy and safety com-
pared to warfarin across both center average TTR and individ-
ual TTR quartiles [62].
Taken together, these findings provide no clear evidence
for an augmented net clinical benefit of DOACs among pa-
tients and populations with poor INR control during warfarin
therapy. Conversely, it shows no clear evidence for the loss of
benefit (and even potential harm) if replacing good INR man-
agement with DOACs. At our institution, we have been for-
tunate to consistently deliver high TTR for our warfarin-
managed patients, and yet, the use of DOAC continues to
rapidly expand.
Choosing a specific antithrombotic agent
To anticoagulate or not anticoagulate
The first step in this decision making process is to deter-
mine whether the patient requires an anticoagulant. The
landscape of antithrombotic decision making for NVAF is
rapidly evolving due, in part, to the introduction of
CHA2DS2-VASc. This scoring tool qualifies more patients
for anticoagulant therapy who were previously deemed
low risk by the CHADS2 scoring tool [63, 64]. In the past,
anticoagulant therapy would have been recommended for
66 % of patients with NVAF [64]. Using this new scoring
system, between 90 and 95 % of patients will qualify for
anticoagulant therapy [65, 66]. The second major advance
altering this landscape is the low bleeding rates associated
with DOAC therapy. In the current climate, the vast ma-
jority of NVAF patients should be offered anticoagulant
therapy. The question is not who should receive anticoag-
ulant therapy, but rather who should not. Identifying the
rare patient who is best served without antithrombotic
therapy includes those with active bleeding, recurrent an-
ticoagulant related bleeding, and those with a CHA2DS2-
VASc score of 0. If the only CHA2DS2-VASc variable is
female gender, then these patients also do not require
anticoagulant therapy. If a NVAF patient had major bleed-
ing on warfarin, anticoagulation often should not be
completely eliminated as the therapeutic option until
apixaban, or lower dose of dabigatran, or edoxaban is
tried.
The traditional warfarin alternative for NVAF patients who
are not suitable, not willing, or not requiring anticoagulation,
has been aspirin. Compared to aspirin in the AVERROES
trial, apixaban showed a similar major bleeding (1.4 vs
1.2 %, p=0.57) and intracranial bleeding rates (11 cases with
apixaban vs 13 with aspirin), but significantly better protec-
tion from stroke (1.6 vs 3.7 %, p<0.001) [6]. These data
suggest that antiplatelet therapy should not be offered for
NVAF unless the patient refuses an anticoagulant or cannot
afford apixaban [16, 20].
Tailoring anticoagulant choice
The next step in the decision making is to identify patient-
specific factors, which would help tailor the anticoagulant
choice (Table 5). For patients at increased risk of thromboem-
bolism with acceptable bleeding risk, we prefer dabigatran
150 mg twice daily. This is the only antithrombotic agent
shown to have superior efficacy in the reduction of ischemic
stroke. The superiority rating noted for apixaban included a
reduction in hemorrhagic stroke in the composite outcome.
Therefore, for relatively young patients with good kidney
function and no history of bleeding, but with the presence of
left atrial appendage thrombus, dabigatran appears to be the
best option. Apixaban does not offer a benefit over warfarin
for this patient profile, as the risk of bleeding, including intra-
cranial bleeding, is relatively low. In this case, edoxaban
30mg will be the least attractive option as it is the only DOAC
with higher ischemic stroke rates compared to warfarin.
For patients at increased risk of bleeding, we prefer
apixaban whereby this agent provided a consistent reduction
in bleeding outcomes regardless of the antithrombotic indica-
tion [4, 67]. Edoxaban would be a reasonable alternative
choice.
Patients with NVAF and recurrent gastrointestinal bleed-
ing pose a particular challenge. Edoxaban at the reduced
dose of 30 mg could be considered in this clinical situation
whereas this is the only preparation associated with a lower
rate of gastrointestinal bleeding compared to warfarin [5].
Although edoxaban 60 mg is recommended for thrombo-
embolism prevention in NVAF patients, current guidelines
encourage a dose reduction in patients with high bleeding
risk [17–20]. Dabigatran 150 mg, rivaroxaban, and
edoxaban 60 mg should be avoided in these patients be-
cause they experienced a higher gastrointestinal bleeding
rate compared to warfarin. Dabigatran 110 mg and
apixaban were associated with gastrointestinal bleed rates
similar to warfarin. Interestingly, dabigatran showed a sim-
ilar proportion of upper and lower gastrointestinal bleeding,
whereas rivaroxaban and apixaban use was associated with
upper gastrointestinal bleeding in two thirds of cases [2–4].
It is speculated that high concentrations of active DOACs
in feces explains the relatively high gastrointestinal bleed-
ing rate of these medications. It is further postulated that
the high concentration of the pro-drug dabigatran etexilate
in the colon becomes activated to dabigatran by mucosal
esterases, and consequently results in bleeding from this
site [7]. For these combined reasons, we favor Xa inhibi-
tors over dabigatran in patients with the prior episodes of
lower gastrointestinal bleeding. This is particularly relevant
for those patients who have undergone recent polypectomy.
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For these patients, it would be reasonable to consider an
alternate anticoagulant for the several week period of
polypectomy site healing.
In the setting of chronic kidney disease, particularly those
patients requiring dialysis, warfarin remains the first choice.
Apixaban is FDA approved for patients with chronic kidney
disease without a recommended dose adjustment regarding of
CKD stage. Until further clinical experience is reported, we
remain cautious regarding use of this drug for patients with
end-stage renal disease.
Once daily dosing has been shown to improve compliance
and adherence over medications requiring multiple daily dos-
ing [68]. To promote adherence, we, therefore, would consider
rivaroxaban or edoxaban.
For patients with significant dyspepsia, peptic ulcer dis-
ease, after vagotomy, gastric drainage procedure, antrectomy,
subtotal or total gastrectomy, and after bariatric procedure, we
suggest avoiding dabigatran which may increase symptoms of
peptic ulcer and/or interfere with medication absorption. Be-
cause of limited gastrointestinal absorption of dabigatran (6–
8 %), even minor fluctuations may have a profound impact on
plasma levels.
Patients who had peripheral embolism as a thrombotic
complication of NVAF might be treated preferentially with
rivaroxaban as it is the only DOACs with improved efficacy
for this type of event.
For patients older than 75 years, we prefer direct Xa inhib-
itors over dabigatran dose of 150 mg because of unfavorable
benefit-risk balance for the latter in elderly.
When treating patients with significant coronary disease,
we suggest avoiding dabigatran until more published experi-
ence is available.
For those patients who are already well-established on a
stable warfarin regimen, there is no need to contemplate a
change. An attractive option for streamlining this regimen is
the addition of home INR monitoring which has been shown
to improve safety, time in the therapeutic range, and patient
satisfaction through increased flexibility and more frequent
INR assessment [69].
Conclusion
Atrial fibrillation is commonly encountered in clinical
practice, and some form of oral anticoagulation is indicat-
ed in almost all patients. Relative to warfarin, the clinical
experience with DOACs has been limited and many ques-
tions remain. Providers must be familiar with the charac-
teristics of these agents and the trials on which their use
was established in order to counsel and care for the grow-
ing number of patients taking them. In general, DOACs
have shown similar efficacy, with better safety, compared
to warfarin for NVAF. This improved safety might further
expand the proportion of NVAF patients who would ben-
efit from anticoagulation therapy. Ultimately, patient-
specific factors and shared decision making should guide
anticoagulant selection.
Table 5 Clinical situation related
preferences for the use of direct
oral anticoagulants































Compliance concerns Edoxaban 60 mg
Rivaroxabana






Edoxaban 60 or 30 mg
Dabigatran 150 mg
aAlthough dosing instruction recommends taking rivaroxaban with evening meal, in reality it means that it needs
to be taken with food either in the morning or in the evening
b Creatinine clearance 30–44 mL/min (chronic kidney disease stage 3B). We remain hesitant to recommend any
of these agents for CKD stages 4 or 5 until published safety data are available
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